Science AI Journal
Medicine · Research topic

Open research questions in Neuroendocrine Tumor Research Advances

126 unresolved questions extracted from the limitations and future-work sections of 270 Neuroendocrine Tumor Research Advances papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • further studies are needed to confirm the prognostic value of the molecular subgroups, - research on the clinical behavior of low-grade NF-pNETs is needed, - studies on the prognostic significance of immunohistochemistry-based subgroups are necessary

    Real-World-Feasible Immunohistochemistry of ATRX, DAXX, and Menin Identifies a Subgroup of Non-Functioning Pancreatic Neuroendocrine Tumors with low Recurrence Risk to Guide De-Escalating Surveillance · 2026 · DOI

  • The aggressive nature of ACTH-producing pNETs. The difficulty in achieving curative resection in locally advanced pNETs. The need for timely biochemical confirmation and a multidisciplinary treatment approach.

    Conversion therapy followed by curative resection in a patient with ACTH-secreting pancreatic neuroendocrine tumor G3: a case report · 2026 · DOI

  • The lack of standardized treatment strategies for locally advanced pNETs. The limited use of conversion therapy in pNETs. The need for a multidisciplinary treatment approach in managing ACTH-secreting pNETs.

    Conversion therapy followed by curative resection in a patient with ACTH-secreting pancreatic neuroendocrine tumor G3: a case report · 2026 · DOI

  • Further studies are needed to validate the PD-L1 IHC 22C3 pharmDx assay for cervical NEC. Research on the effects of HPV-driven oncogenesis on the cervical immune microenvironment is needed. Studies evaluating associations between PD-L1 scores and clinicopathologic or clinical outcome variables in cervical NEC are required.

    Immunohistochemical profiling of PD-L1 expression in neuroendocrine carcinoma of the uterine cervix · 2026 · DOI

  • The clinical interpretation of PD-L1 assessment in cervical NEC remains uncertain. The relevant PD-L1 assays and scoring thresholds have not been specifically validated for cervical NEC. There is a need for novel systemic therapies for cervical NEC.

    Immunohistochemical profiling of PD-L1 expression in neuroendocrine carcinoma of the uterine cervix · 2026 · DOI

  • One challenge is the heterogeneous expression of CCKBR in tumors. Another challenge is the physiologic uptake of radiolabeled peptides in normal tissues, such as the gastric mucosa and renal tubular system. Additionally, there is a need for standardized imaging, dosimetry, and treatment protocols to support the clinical translation of CCKBR-targeted theranostics.

    CCKBR (Gastrin Receptor) as a Theranostic Target in Oncology: Biological Rationale, Diagnostic Imaging, and Next-Generation Peptide-Based Drug Development · 2026 · DOI

  • The gap in current research is the limited clinical establishment of CCKBR-targeted theranostics. Another gap is the need for standardized imaging, dosimetry, and treatment protocols. Additionally, there is a lack of prospective clinical evidence to support the use of CCKBR-targeted theranostics.

    CCKBR (Gastrin Receptor) as a Theranostic Target in Oncology: Biological Rationale, Diagnostic Imaging, and Next-Generation Peptide-Based Drug Development · 2026 · DOI

  • the available data remain limited and primarily derived from isolated case reports, - no exclusions were made based on article type, - the search was limited to articles published in English and Spanish

    Neuroendocrine neoplasms as a lynch syndrome manifestation: a case report and comprehensive literature review · 2025 · DOI

  • The lack of a definitive association between Lynch syndrome and neuroendocrine neoplasms. The limited understanding of the underlying mechanisms. The need for further research to determine whether Lynch syndrome predisposes individuals to neuroendocrine neoplasms.

    Neuroendocrine neoplasms as a lynch syndrome manifestation: a case report and comprehensive literature review · 2025 · DOI

  • Optimizing PRRT in neuroendocrine tumors is challenging due to the risk of undertreatment or unnecessary toxicity. Individualized dosimetry and tandem-PRRT with 90Y/177Lu require complex technical and logistical considerations. The study must balance the need for effective treatment with the risk of adverse events.

    Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial · 2025 · DOI

  • Long-term follow-up to clarify the impact on efficacy, - Further development of PRRT in neuroendocrine tumors, - Investigation of the effects of dosimetry-guided PRRT strategies on progression-free survival and overall survival

    Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial · 2025 · DOI

  • Prospective clinical trials are warranted to confirm these findings and explore underlying mechanisms.

    Survival Benefits of GLP-1 Receptor Agonists in Patients with Neuroendocrine Neoplasms: A Large-Scale Propensity-Matched Cohort Study · 2025 · DOI

  • Glucagon-like peptide-1 receptor agonists (GLP-1Ra) have demonstrated favorable results in preclinical studies, but their impact on NEN outcomes remains unexplored.

    Survival Benefits of GLP-1 Receptor Agonists in Patients with Neuroendocrine Neoplasms: A Large-Scale Propensity-Matched Cohort Study · 2025 · DOI

  • Background: There is limited data on somatostatin receptor (SSTR) expression of metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) using modern imaging techniques and stratifying by primary site and tumor grade (G).

    Somatostatin Receptor Expression of Gastroenteropancreatic Neuroendocrine Tumors: A Comprehensive Analysis in the Era of Somatostatin Receptor PET Imaging · 2025 · DOI

  • Currently, there are no studies on predictive models for the risk of distant metastasis in GEP-NETs.

    Risk factors, prognostic factors, and nomograms for distant metastases in patients with gastroenteropancreatic neuroendocrine tumors: a population-based study · 2024 · DOI

  • Especially in a metastasized tumor stage, the role of surgery, peptide receptor radionucleotide therapy (PRRT), and systemic chemotherapy is not clearly defined.

    Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3 · 2024 · DOI

  • Future research should focus on refining LB methods, standardising protocols and exploring applications in high-grade NENs.

    The Role of Liquid Biopsy in Gastroenteropancreatic Neuroendocrine Neoplasms · 2024 · DOI

  • Physiological gallbladder uptake limits the interpretation of 18F-NOTANOC PET/CT imaging. There is a need for a method to reduce this uptake.

    Dietary Intervention to Reduce Physiological Gallbladder Uptake and Improve Interpretation of F-18 NOTANOC PET/CT · 2026 · DOI

  • The heterogeneous nature of neuroendocrine tumors. The need for effective treatment options for advanced disease. The importance of evaluating the safety and efficacy of [177Lu]Lu-DOTATATE in real-world settings.

    Safety and Efficacy of [177Lu]Lu-DOTATATE in Neuroendocrine Tumors at a Tertiary Cancer Center in Jordan: A Multinational Arab Cohort · 2026 · DOI

  • There is a need for real-world evidence supporting the clinical safety and effectiveness of [177Lu]Lu-DOTATATE. The study aims to fill this gap by evaluating the safety and efficacy of [177Lu]Lu-DOTATATE in a consecutive cohort of patients with advanced, well-differentiated NETs.

    Safety and Efficacy of [177Lu]Lu-DOTATATE in Neuroendocrine Tumors at a Tertiary Cancer Center in Jordan: A Multinational Arab Cohort · 2026 · DOI

  • The understanding of DIPNECH remains limited. There are currently no established guidelines for the management of DIPNECH. The study highlights the need for further research into the diagnosis, treatment, and management of DIPNECH.

    Metastatic Neuroendocrine Lesions in Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH): A Narrative Review and Case Series · 2026 · DOI

  • The prognosis for NECs remains poor despite similar surgical management. There is a lack of understanding and management of LCNEC of the ampulla of Vater.

    Large-Cell Neuroendocrine Carcinoma of the Ampulla of Vater: A Systematic Literature Review of a Rare and Aggressive Entity · 2026 · DOI

  • The diagnosis of early ampullary tumors is challenging due to their complex surrounding structures and deep anatomical location. The diagnostic accuracy of imaging modalities is limited by the ampulla's anatomy.

    Ampullary carcinoma detected incidentally during ERCP: a case report and literature review · 2026 · DOI

  • The incidence of NUT carcinoma is not described. There is a need for correct diagnosis of NUT carcinoma.

    An Intriguing Case of Chemical Mimicry: Raised AFP Levels in NUT Carcinoma in Anterior Mediastinum · 2026 · DOI

  • The heterogeneity of NETs poses challenges for therapeutic decision-making. The current WHO classification is based on limited parameters. Ki-67 index and mitotic count can be difficult to assess in small tissue samples.

    Three-Tier Prognostic Stratification of Lung Carcinoids (NET G1-G2-G3) by Multivariable, Data-Driven Integration of Ki-67 and Mitotic Count · 2026 · DOI

Most-cited papers in Neuroendocrine Tumor Research Advances

Most recent work

Find a gap in your own Neuroendocrine Tumor Research Advances sub-topic

This page shows what the Neuroendocrine Tumor Research Advances literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
2,044 open questions
Substance Abuse Treatment and Outcomes
1,964 open questions
Smoking Behavior and Cessation
990 open questions
Dementia and Cognitive Impairment Research
974 open questions
Innovations in Medical Education
960 open questions
Physical Activity and Health
923 open questions
Attention Deficit Hyperactivity Disorder
839 open questions
Schizophrenia research and treatment
709 open questions
126 open questions have been extracted from the limitations and future-work passages of 270 Neuroendocrine Tumor Research Advances papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.